Cognition Therapeutics (CGTX) reported a positive outcome of an analysis of masked data from the ongoing ‘MAGNIFY’ Phase 2 trial of zervimesine in adults with geographic atrophy secondary to dry age-related macular degeneration. The purpose of this type of analysis, known as a “futility analysis” is to determine if a drug candidate is showing signals of efficacy. Cognition’s contract research organization conducted the analysis to protect the integrity of the clinical trial. Results of the futility analysis from the first 57 participants who completed at least 6 months of dosing showed that zervimesine-treated patients were experiencing a slower lesion growth rate than those on placebo.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition VP co-hosting workshop at Neuroimmunology Drug Development Summit
- Cognition announces publication of zervimesine manufacturing process
- Cognition Therapeutics price target raised to $2 from $1.50 at B. Riley
- Cognition announces Phase 2 ‘SHIMMER’ study to be presented at ILBDC
- Cognition Therapeutics Shows Promising Phase 2 Study Results